Parameters of Vitamin D Metabolism in Patients with Hypoparathyroidism
Authors:
- Artem ZhukovAZArtem Zhukov
- Alexandra PovaliaevaAPAlexandra Povaliaeva
- Zaur AbilovZAZaur Abilov
- Elena KovalevaEKElena Kovaleva
- Liliya UsoltsevaLULiliya Usoltseva
- Anna EremkinaAEAnna Eremkina
- Vitaliy IoutsiVIVitaliy Ioutsi
- Larisa DzeranovaLDLarisa Dzeranova
- Ekaterina PigarovaEPEkaterina Pigarova
- Liudmila RozhinskayaLRLiudmila Rozhinskaya
- Natalia MokryshevaNMNatalia Mokrysheva
Open Access
- 16 December 2022
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 12 (12) , 1279
Abstract
Only a few studies evaluating the metabolism of vitamin D in patients with hypoparathyroidism (HypoPT) have been performed thus far, and, in particular, they mainly investigated the process of vitamin D activation (specifically, 1α-hydroxylation). This study, therefore, aimed to evaluate the extended spectrum of vitamin D metabolites in patients with HypoPT compared to healthy individuals. We examined 38 adult patients with chronic HypoPT in comparison to 38 healthy adults. The assessment included biochemical parameters (total calcium, albumin, phosphorus, creatinine, and magnesium), parathyroid hormone (PTH), and vitamin D metabolites (25(OH)D3, 25(OH)D2, 1,25(OH)2D3, 3-epi-25(OH)D3, and 24,25(OH)2D3) in serum. Our data show that an adequate level of 25(OH)D3 (median 35.3 (29.6; 42.0) ng/mL) is achieved with standard doses of cholecalciferol (median 2000 (2000; 2500) IU per day) in HypoPT patients. They also presented with supraphysiological levels of 1,25(OH)2D3 (median 71 (47; 96) vs. 40 (34; 59) pg/mL, p < 0.001) and the increased production of inactive metabolite (median 24,25(OH)2D3 3.8 (3.0; 5.1) vs. 1.9 (1.3; 2.7) ng/mL, p < 0.001; median 25(OH)D3/24,25(OH)2D3 ratio 8.9 (7.6; 11.1) vs. 13.5 (11.1; 17.0), p < 0.001) as compared to the control group. This might be a consequence of the therapy received (treatment with activated vitamin D) and the pathophysiology of the disease (lack of PTH). The abnormality of vitamin D metabolism does not seem to interfere with the achievement of hypoparathyroidism compensation.Keywords
Funding Information
- Russian Science Foundation (19-15-00243-P)
This publication has 27 references indexed in Scilit:
- Vitamin D Metabolism, Mechanism of Action, and Clinical ApplicationsChemistry & Biology, 2014
- Extrarenal Vitamin D Activation and Interactions Between Vitamin D2, Vitamin D3, and Vitamin D AnalogsAnnual Review of Nutrition, 2013
- The C-3 Epimer of 25-Hydroxyvitamin D3Is Present in Adult SerumThe Journal of Clinical Endocrinology & Metabolism, 2012
- Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2011
- Vitamin D DeficiencyNew England Journal of Medicine, 2007
- Extrarenal Production of Calcitriol in Normal and Uremic Humans*The Journal of Clinical Endocrinology & Metabolism, 1991
- Comparison of serum total calcium, albumin-corrected total calcium, and ionized calcium in 1213 patients with suspected calcium disordersScandinavian Journal of Clinical and Laboratory Investigation, 1989
- Extra-renal production of calcitriol in chronic renal failureKidney International, 1988
- Vitamin D Metabolism in HypoparathyroidismThe Journal of Clinical Endocrinology & Metabolism, 1980
- Treatment of Hypoparathyroidism and Pseudohypoparathyroidism with Metabolites of Vitamin D: Evidence for Impaired Conversion of 25-Hydroxyvitamin D to 1α,25-Dihydroxyvitamin DNew England Journal of Medicine, 1975